Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000937 · ClinicalTrials.gov registry record · Phase 3
Study and Treatment of Post Lyme Disease (STOP-LD)
A Phase 3 study of Lyme Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT00000937: Completed Phase 3 study of Lyme Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000937 is a Phase 3 study of Lyme Disease that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 55 participants, below the 3,868-participant average among 9 other Lyme Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000937, a Phase 3 study of Lyme Disease, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how well antibiotics work in reducing chronic fatigue symptoms, such as tiredness, in patients that were treated for Lyme Disease. Fatigue is a common symptom of Lyme Disease. When fatigue does not improve after treatment, patients are considered to have Post Lyme Syndrome (PLS). The chronic fatigue seen in these patients appears to be related to the initial infection which causes Lyme Disease. It is believed, but not proven, that treatment with antibiotics may be effective in relieving chronic fatigue in PLS patients.
Conditions Studied
Interventions
- DRUG Antibiotics
Study Locations (1)
New York
- Lauren Krupp - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
What the finished NCT00000937 record still lists
NCT00000937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 3,868-participant average among 9 other Lyme Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Lyme Disease appearing as the primary indexed condition, and to 1 intervention - of which Antibiotics is the first listed.
NCT00000937 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00000937 about?
NCT00000937 is a clinical study titled "Study and Treatment of Post Lyme Disease (STOP-LD)". The purpose of this study is to see how well antibiotics work in reducing chronic fatigue symptoms, such as tiredness, in patients that were treated for Lyme Disease. Fatigue is a common symptom of Lyme Disease. When fatigue does not improve after treatment, patients are considered to have Post Lyme...
What is the current status of trial NCT00000937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. Estimated completion is 2005-11.
What conditions does trial NCT00000937 study?
This clinical trial studies the following conditions: Lyme Disease.
What interventions are being tested in trial NCT00000937?
The interventions under investigation include: Antibiotics (DRUG).
Who is sponsoring clinical trial NCT00000937?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000937 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lyme Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000937's enrollment target sits among peer trials
55 7th of 9 higher than 3 of 9 other Lyme Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lyme Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
ACTIVE NOT RECRUITING · Phase 3
-
Lyme Disease Prevention Program
COMPLETED · Phase 3
-
Human Immune Response to Ixodes Scapularis Tick Bites
RECRUITING · Phase 1
-
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
RECRUITING
-
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
RECRUITING
-
Navigating Pregnancy and Parenthood With Lyme Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy